Tirzepatide

S

Tirzepatide is a dual GIP and GLP-1 receptor agonist studied across metabolic, appetite, and body-composition research.

What is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist studied across metabolic, appetite, and body-composition research.

Tirzepatide dosage snapshot

Route
subQ
Dose range
2.5-15 mg titrated
Frequency
1x weekly
Duration
long-term studies

Based on reported research sources; not a dosing instruction.

Potential benefits

  • Weight loss
  • Glucose control
  • Appetite control
  • Metabolic health
  • Body composition

Safety profile

Low risk
  • Common: Nausea, diarrhea, vomiting, constipation, and appetite suppression.
  • Less common: Injection-site reactions, fatigue, reflux, or abdominal discomfort.
  • Caution: Dose escalation and prior incretin exposure can strongly affect tolerability.

Storage and handling

Store according to product-label instructions and batch handling notes. Lyophilized research peptides are commonly kept dry, protected from light, and handled with clean laboratory technique.

Related peptides